Release of the Pre-Assembled naRNA-LL37 Composite DAMP Re-Defines Neutrophil Extracellular Traps (NETs) as Intentional DAMP Webs
Francesca Bork,Carsten Leo Greve,Christine Youn,Sirui Chen,Yu Wang,Masoud Nasri,Jule Focken,Jasmin Scheurer,Pujan Engels,Marissa Dubbelaar,Katharina Hipp,Birgit Schittek,Stefanie Bugl,Markus W. Löffler,Julia Skokowa,Nate K. Archer,Alexander Norman Rainer Weber
DOI: https://doi.org/10.2139/ssrn.4244243
2022-01-01
SSRN Electronic Journal
Abstract:Neutrophil extracellular traps (NETs) are a key antimicrobial feature of cellular innate immunity mediated by polymorphonuclear neutrophils (PMNs), the primary human leukocyte population. NETs trap and kill microbes but have also been linked to inflammation, e.g. atherosclerosis, arthritis or psoriasis by unknown mechanisms. We here characterize naRNA (NET-associated RNA), as a new canonical, abundant, and unexplored inflammatory NET component. naRNA, upon release by NET formation, drove further NET formation in naïve PMN, and induced macrophage and keratinocyte activation via TLR8 in humans and Tlr13 in mice, in vitro and in vivo. Importantly, in vivo naRNA strongly drove skin inflammation, whereas genetic ablation of RNA sensing drastically ameliorated psoriatic skin inflammation. Rather than accidentally assembling with LL37 on the NET, naRNA was intracellularly pre-associated in resting neutrophils as a ‘composite DAMP’, thus highlighting NET formation as a DAMP release process. This re-defines sterile NETs as an intentionally inflammatory agent, signaling and amplifying neutrophil activation. Moreover, in the many conditions previously linked to NETs and extracellular RNA, TLR-mediated naRNA sensing emerges as both potential cause and new intervention target.Funding Information: The study was supported by the Deutsche Forschungsgemeinschaft (German Research Foundation, DFG) grants CRC TR156 “The skin as an immune sensor and effector organ – Orchestrating local and systemic immunity” (to FB, CG, JF, JS, BS and ANRW), NIH grants R01AI146177, R01AR073665, and R01AR069502 (to NKA). NKA. has received previous grant support from Pfizer and Boehringer Ingelheim and was a paid consultant for Janssen Pharmaceuticals. Infrastructural funding was provided by the University of Tübingen, the University Hospital Tübingen and the DFG Clusters of Excellence "iFIT – Image-Guided and Functionally Instructed Tumor Therapies" (EXC 2180, to AW, PE, BS and MWL), “CMFI – Controlling Microbes to Fight Infection (EXC 2124 to AW and BS). Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) im Rahmen der Exzellenzstrategie des Bundes und der Länder - EXC 2180 and EXC 2124. Declaration of Interests: The authors declare no competing financial interests.Ethics Approval Statement: All healthy donors included in this study provided their written informed consent before participation. Approval for use of biomaterials was obtained for this project by the local ethics committee of the Medical Faculty Tübingen in accordance with the principles laid down in the Declaration of Helsinki as well as applicable laws and regulations.All animal experiments were approved by the Johns Hopkins University Animal Care and Use Committee (MO21M378).